HealthNet MEA brings EpiFaith Smart Syringe to the UAE

HealthNet MEA has launched Flat Medical’s EpiFaith Smart Syringe and EpiFaith CV in the UAE, giving healthcare professionals objective pressure indication for epidural and central venous access procedures. The devices are designed to complement clinician judgment, and HealthNet MEA says the launch follows broader adoption in Europe, North America and Asia.

Why it matters: - The EpiFaith® Series is designed to add objective pressure indication to procedures that have traditionally relied on tactile judgment alone. - The launch gives UAE healthcare professionals access to devices intended to support consistency in epidural localization and central venous access. - HealthNet MEA is the exclusive importer and distributor of the EpiFaith® Series in the UAE.

What happened: - HealthNet MEA announced the UAE launch of the EpiFaith® Smart Syringe and EpiFaith® CV, developed by Flat Medical. - The launch was announced in Dubai on June 29, 2026. - The EpiFaith® Smart Syringe is designed for epidural procedures. - The EpiFaith® CV is designed for central venous catheterisation. - HealthNet MEA posted a LinkedIn showcase page for the company.

The details: - The EpiFaith® Smart Syringe objectively detects the pressure change associated with entry into the epidural space. - The device provides a clear visual indication to the clinician. - The visual guidance is designed to complement tactile assessment while allowing continuous focus on needle advancement. - EpiFaith® CV provides real-time pressure indication during vascular access. - The device is designed to help differentiate venous from arterial access when blood color alone is less reliable. - The EpiFaith® Series is designed to fit into existing clinical workflows. - The devices are intended for use by appropriately trained healthcare professionals in line with approved indications, instructions for use, institutional policies and applicable regulatory requirements. - HealthNet MEA is an MOHAP/EDE-licensed establishment based in Dubai. - HealthNet MEA says it provides regulatory affairs, market access, importation, warehousing, demand-generation and distribution support for healthcare technologies.

Between the lines: - The launch reflects a push toward tools that reduce reliance on subjective cues in high-stakes procedures. - The company is positioning the EpiFaith® Series as support for clinicians, not a replacement for procedural judgment. - The announcement leans on clinical studies cited by the company, but the release does not identify the journals or study details. - Reported findings from published studies included lower rates of unintended epidural or vascular dilations, fewer false-positive loss-of-resistance readings and fewer transient procedure-related complications. - The devices have also seen adoption in Europe, North America and Asia, including teaching hospitals and healthcare systems with strict clinical governance and procedural training. - Flat Medical says the devices were developed to support precision and consistency across anesthesia and vascular access applications.

What's next: - HealthNet MEA said it will support adoption of the EpiFaith® Series within UAE clinical practice. - Broader use in UAE hospitals will depend on training, institutional policies and regulatory requirements. - The company is likely to use the launch to expand awareness among clinicians working in anesthesia and vascular access.